213 related articles for article (PubMed ID: 36987403)
1. Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review.
Daksla N; Wang A; Jin Z; Gupta A; Bergese SD
Drug Des Devel Ther; 2023; 17():875-886. PubMed ID: 36987403
[TBL] [Abstract][Full Text] [Related]
2. APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.
Singla NK; Skobieranda F; Soergel DG; Salamea M; Burt DA; Demitrack MA; Viscusi ER
Pain Pract; 2019 Sep; 19(7):715-731. PubMed ID: 31162798
[TBL] [Abstract][Full Text] [Related]
3. Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis.
Bergese S; Berkowitz R; Rider P; Ladouceur M; Griffith S; Segura Vasi A; Cochrane K; Wase L; Demitrack MA; Habib AS
Pain Res Manag; 2020; 2020():7492865. PubMed ID: 33163127
[TBL] [Abstract][Full Text] [Related]
4. Evaluating oliceridine as a treatment option for moderate to severe acute post-operative pain in adults.
Jin Z; Zhu M; Gupta A; Page C; Gan TJ; Bergese SD
Expert Opin Pharmacother; 2022 Jan; 23(1):9-17. PubMed ID: 34534033
[TBL] [Abstract][Full Text] [Related]
5. Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain.
Gan TJ; Wase L
Drugs Today (Barc); 2020 Apr; 56(4):269-286. PubMed ID: 32309822
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain.
Tan HS; Habib AS
Expert Opin Drug Saf; 2021 Nov; 20(11):1291-1298. PubMed ID: 34370562
[TBL] [Abstract][Full Text] [Related]
7. Preclinical discovery and development of oliceridine (Olinvyk®) for the treatment of post-operative pain.
Azzam AAH; Lambert DG
Expert Opin Drug Discov; 2022 Mar; 17(3):215-223. PubMed ID: 34817313
[TBL] [Abstract][Full Text] [Related]
8. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.
Singla N; Minkowitz HS; Soergel DG; Burt DA; Subach RA; Salamea MY; Fossler MJ; Skobieranda F
J Pain Res; 2017; 10():2413-2424. PubMed ID: 29062240
[TBL] [Abstract][Full Text] [Related]
9. Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials.
Hammer GB; Khanna AK; Michalsky C; Wase L; Demitrack MA; Little R; Fossler MJ; Ayad S
Pain Ther; 2021 Dec; 10(2):1343-1353. PubMed ID: 34351590
[TBL] [Abstract][Full Text] [Related]
10. Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events.
Simpson KN; Fossler MJ; Wase L; Demitrack MA; Wandstrat TL
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):671-681. PubMed ID: 35129031
[TBL] [Abstract][Full Text] [Related]
11. Oliceridine for the Management of Acute Postoperative Pain.
Liu Y; Hu Q; Yang J
Ann Pharmacother; 2021 Oct; 55(10):1283-1289. PubMed ID: 33423508
[TBL] [Abstract][Full Text] [Related]
12. Opioid MOP receptor agonists in late-stage development for the treatment of postoperative pain.
Qiu Q; Chew JC; Irwin MG
Expert Opin Pharmacother; 2022 Nov; 23(16):1831-1843. PubMed ID: 36302462
[TBL] [Abstract][Full Text] [Related]
13. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy.
Viscusi ER; Skobieranda F; Soergel DG; Cook E; Burt DA; Singla N
J Pain Res; 2019; 12():927-943. PubMed ID: 30881102
[TBL] [Abstract][Full Text] [Related]
14. Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain - A Review of Current Evidence.
Tan HS; Habib AS
J Pain Res; 2021; 14():969-979. PubMed ID: 33889018
[TBL] [Abstract][Full Text] [Related]
15. Oliceridine in the treatment of moderate to severe acute pain.
Eleswarpu SS; Habib AS
Pain Manag; 2021 May; 11(3):237-248. PubMed ID: 33455450
[TBL] [Abstract][Full Text] [Related]
16. Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review.
Wang A; Murphy J; Shteynman L; Daksla N; Gupta A; Bergese S
Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38256863
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain.
Ayad S; Demitrack MA; Burt DA; Michalsky C; Wase L; Fossler MJ; Khanna AK
Clin Drug Investig; 2020 Aug; 40(8):755-764. PubMed ID: 32583295
[TBL] [Abstract][Full Text] [Related]
18. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.
Azevedo Neto J; Costanzini A; De Giorgio R; Lambert DG; Ruzza C; Calò G
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854452
[TBL] [Abstract][Full Text] [Related]
19. A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain.
Viscusi ER
Expert Rev Neurother; 2022 Jun; 22(6):419-426. PubMed ID: 35502668
[TBL] [Abstract][Full Text] [Related]
20. ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy.
Bergese SD; Brzezinski M; Hammer GB; Beard TL; Pan PH; Mace SE; Berkowitz RD; Cochrane K; Wase L; Minkowitz HS; Habib AS
J Pain Res; 2019; 12():3113-3126. PubMed ID: 31814753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
